Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer's disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using serial (11)C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial structural magnetic resonance imaging. We studied 21 healthy cognitively normal subjects, 32 with amnestic mild cognitive impairment and 8 with Alzheimer's disease. Subjects were drawn from two sources--ongoing longitudinal registries at Mayo Clinic, and the Alzheimer's disease Neuroimaging Initiative (ADNI). All subjects underwent clinical assessments, MRI and PIB studies at two time points, approximately one year apart. PIB retention was quantified in global cortical to cerebellar ratio units and brain atrophy in units of cm(3) by measuring ventricular expansion. The annual change in global PIB retention did not differ by clinical group (P = 0.90), and although small (median 0.042 ratio units/year overall) was greater than zero among all subjects (P < 0.001). Ventricular expansion rates differed by clinical group (P < 0.001) and increased in the following order: cognitively normal (1.3 cm(3)/year) < amnestic mild cognitive impairment (2.5 cm(3)/year) < Alzheimer's disease (7.7 cm(3)/year). Among all subjects there was no correlation between PIB change and concurrent change on CDR-SB (r = -0.01, P = 0.97) but some evidence of a weak correlation with MMSE (r =-0.22, P = 0.09). In contrast, greater rates of ventricular expansion were clearly correlated with worsening concurrent change on CDR-SB (r = 0.42, P < 0.01) and MMSE (r =-0.52, P < 0.01). Our data are consistent with a model of typical late onset Alzheimer's disease that has two main features: (i) dissociation between the rate of amyloid deposition and the rate of neurodegeneration late in life, with amyloid deposition proceeding at a constant slow rate while neurodegeneration accelerates and (ii) clinical symptoms are coupled to neurodegeneration not amyloid deposition. Significant plaque deposition occurs prior to clinical decline. The presence of brain amyloidosis alone is not sufficient to produce cognitive decline, rather, the neurodegenerative component of Alzheimer's disease pathology is the direct substrate of cognitive impairment and the rate of cognitive decline is driven by the rate of neurodegeneration. Neurodegeneration (atrophy on MRI) both precedes and parallels cognitive decline. This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Efforts continue to be placed on the early detection of AD as changes in brain chemistry begin to occur 20 years or more prior to the onset of noticeable cognitive symptoms [137,138,139,140].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these symptoms are new to the individual affected, the brain changes that cause them are thought to begin 20 years or more before symptoms start.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319 · cited 1×
“The automated anatomic labelling (AAL) atlas (Tzourio-Mazoyer et al., 2002) was modified in-house to contain the following labelled regions of interest: right and left parietal, temporal, prefrontal, primary sensory -motor, orbito frontal, anterior cingulate, posterior cingulate/ precuneus and occipital.”
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citation
Cited by
Items 501–600 of 1,000
The Aging Brain and Neurodegenerative Diseases
Duncan, G. W. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.07.008 · Cited by 42
Should We Disclose Amyloid Imaging Results to Cognitively Normal Individuals?
Grill, J. D., Johnson, D. K., & Burns, J. M. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.75 · Cited by 36
Physical activity across adulthood and subjective cognitive function in older men
Fondell, E., Townsend, M. K., Unger, L. D., Okereke, O. I., Grodstein, F., Ascherio, A., & Willett, W. C. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0331-2 · Cited by 37
Sojkova, J., & M. Resnick, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745375 · Cited by 36
Functional MRI and neural responses in a rat model of Alzheimer's disease
Sanganahalli, B. G., Hermán, P., Behar, K. L., Blumenfeld, H., Rothman, D. L., & Hyder, F. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.099 · Cited by 37
Using Structural and Diffusion Magnetic Resonance Imaging To Differentiate the Dementias
Suri, S., Topiwala, A., Mackay, C. E., Ebmeier, K. P., & Filippini, N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0475-3 · Cited by 42
Wolf, D., 1, A. F. A. F. T. A. D. N. I., Fischer, F. U., Scheurich, A., & Fellgiebel, A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150049 · Cited by 35
The prognostic value of amyloid imaging
Gelosa, G., & Brooks, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2108-x · Cited by 36
Chang, Y., Huang, C., Chang, Y., Chen, N.-C., Lin, K., Yan, T.-C., Chang, W., Chen, S.-F., Lui, C., Lin, P., et al. (2015) · Medicine · doi:10.1097/md.0000000000000763 · Cited by 36
Kuzuya, A., Zoltowska, K. M., Post, K. L., Arimon, M., Li, X., Svirsky, S. E., Maesako, M., Muzikansky, A., Gautam, V., Kovacs, D. M., et al. (2016) · BMC Biology · doi:10.1186/s12915-016-0248-3 · Cited by 39
In vivo Depiction of α7 Nicotinic Receptor Loss for Cognitive Decline in Alzheimer’s Disease
Nakaizumi, K., Ouchi, Y., Terada, T., Yoshikawa, E., Kakimoto, A., Isobe, T., Bunai, T., Yokokura, M., Suzuki, K., & Magata, Y. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170591 · Cited by 36
Using Biomarkers to Improve Detection of Alzheimer’s Disease
Biagioni, M. C., & Galvin, J. E. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.11 · Cited by 40
Cselényi, Z., & Farde, L. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.66 · Cited by 34
Mhatre, S. D., Michelson, S. J., Gomes, J., Tabb, L. P., Saunders, A. J., & Marenda, D. R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.08.021 · Cited by 37
Molecular Network Analysis of the Urinary Proteome of Alzheimer’s Disease Patients
Watanabe, Y., Hirao, Y., Kasuga, K., Tokutake, T., Semizu, Y., Kitamura, K., Ikeuchi, T., Nakamura, K., & Yamamoto, T. (2019) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000496100 · Cited by 32
Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions
Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9190-2 · Cited by 34
“…temporal and parietal lobes; at the time of the first diagnosis of AD, the pathology develops a greater severity and widespread pattern encompassing the medial temporal lobe, the temporoparietal cortices, and the frontal lobe (Jack et al. 2004, 2008, 2009; Barnes et al. 2006; Carlson et al. 2008).”
BackgroundCerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease
Wang, F., Gordon, B. A., Ryman, D. C., Ma, S., Xiong, C., Hassenstab, J., Goate, A., Fagan, A. M., Cairns, N. J., Marcus, D. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001903 · Cited by 34
Nurses’ perceptions of mandatory bedside clinical handovers: An Australian hospital study
Slade, D., Murray, K. A., Pun, J., & Eggins, S. (2018) · Journal of Nursing Management · doi:10.1111/jonm.12661 · Cited by 34
Data-driven causal model discovery and personalized prediction in Alzheimer's disease
Zheng, H., Petrella, J. R., Doraiswamy, P. M., Lin, G., Hao, W., & Initiative, A. D. N. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00632-7 · Cited by 34
Wang, M.-D., Zhang, S., Liu, X., Wang, P., Zhu, Y.-F., Zhu, J., Lv, C.-S., Li, S., Liu, S.-F., & Wen, L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01125-3 · Cited by 34
Amyloid imaging with [18F]florbetapir in geriatric depression: early‐onset versus late‐onset
Tateno, A., Sakayori, T., Higuchi, M., Suhara, T., Ishihara, K., Kumita, S., Suzuki, H., & Okubo, Y. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4215 · Cited by 36
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 37
Improving Alzheimer's disease phase II clinical trials
Greenberg, B., Carrillo, M. C., Ryan, J. M., Gold, M., Gallagher, K., Grundman, M., Berman, R., Ashwood, T., & Siemers, E. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.02.002 · Cited by 37
Amyloid Imaging in Early Detection of Alzheimer’s Disease
Nordberg, A. K. (2010) · Neurodegenerative Diseases · doi:10.1159/000289223 · Cited by 35
A brain stress test: Cerebral perfusion during memory encoding in mild cognitive impairment
Xie, L., Dolui, S., Das, S. R., Stockbower, G. E., Daffner, M., Rao, H., Yushkevich, P. A., Detre, J. A., & Wolk, D. A. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.03.002 · Cited by 35
Petersen, R. C., & Trojanowski, J. Q. (2009) · JAMA · doi:10.1001/jama.2009.1073 · Cited by 35
Self-citationRadiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease
Någren, K., Halldin, C., & Rinne, J. O. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1301-z · Cited by 37
Amyloid imaging and memory change for prediction of cognitive impairment
Resnick, S. M., & Sojkova, J. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt62 · Cited by 33
Akasaka, T., Watanabe, H., & Ono, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01057 · Cited by 34
ten Kate, M., Barkhof, F., Visser, P. J., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Tijms, B. M. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0299-x · Cited by 35
Lee, J., Ahn, S.-Y., Lee, H. A., Won, K. S., Chang, H. W., Oh, J. S., & Kim, H. W. (2018) · Food & Nutrition Research · doi:10.29219/fnr.v62.1415 · Cited by 35
Human APOE genotype affects intraneuronal A 1-42 accumulation in a lentiviral gene transfer model
Zhao, W., Dumanis, S. B., Tamboli, I. Y., Rodriguez, G. A., Jo LaDu, M., Moussa, C. E. H., & William Rebeck, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt525 · Cited by 32
Smith, G. S., Kuwabara, H., Yan, H., Nassery, N., Yoon, M., Kamath, V., Kraut, M. A., Gould, N. F., Savonenko, A. V., Coughlin, J. M., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230570 · Cited by 34
Multimodal Imaging of Alzheimer Pathophysiology in the Brain′s Default Mode Network
Shin, J., Kepe, V., Small, G. W., Phelps, M. E., & Barrio, J. R. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/687945 · Cited by 31
How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis?
Kempton, M. J., & McGuire, P. K. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.006 · Cited by 34
Cho, E. B., Shin, H.-Y., Park, S. E., Chun, P., Jang, H. R., Yang, J.-J., Kim, H. J., Kim, Y. J., Jung, N., Lee, J. S., et al. (2016) · Scientific Reports · doi:10.1038/srep20692 · Cited by 33
Increase in brain atrophy after subdural hematoma to rates greater than associated with dementia
Zahid, A. B., Balser, D. Y., Thomas, R., Mahan, M. Y., Hubbard, M. E., & Samadani, U. (2018) · Journal of neurosurgery · doi:10.3171/2017.8.jns17477 · Cited by 32
Wu, K., Lin, K., Chen, C., Chen, C., Liu, C., Huang, S., Yen, T., & Hsiao, I. (2018) · Brain and Behavior · doi:10.1002/brb3.1016 · Cited by 34
Armstrong, N. M., Huang, C.-W., Williams, O. A., Bilgel, M., An, Y., Doshi, J. J., Erus, G., Davatzikos, C. A., Wong, D. F., Ferrucci, L., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101769 · Cited by 34
Mathematical analysis for stochastic model of Alzheimer’s disease
Zhang, Y., & Wang, W. (2020) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2020.105347 · Cited by 33
Smith, G. S., Workman, C. I., Protas, H. D., Su, Y., Savonenko, A. V., Kuwabara, H., Gould, N. F., Kraut, M. A., Joo, J. H., Nandi, A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01539-9 · Cited by 34
Use of Biomarkers in Clinical Trials of Alzheimer Disease: From Concept to Application
Wu, L., Rosa‐Neto, P., & Gauthier, S. G. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256467 · Cited by 34
Park, S. E., Kim, H., Lee, J., Lee, N. K., Hwang, J. W., Yang, J., Ye, B. S., Cho, H., Kim, H. J., Kim, Y. J., et al. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000733 · Cited by 33
Quevenco, F. C., Schreiner, S. J., Preti, M. G., Bergen, J. M. G. V., Kirchner, T., Wyss, M. T., Steininger, S. C., Gietl, A. F., Leh, S. E., Buck, A., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101776 · Cited by 33
Longitudinal cognitive decline in the AIBL cohort: The role of APOE ε4 status
Albrecht, M. A., Szoeke, C. E. I., Maruff, P. T., Savage, G. R., Lautenschlager, N. T., Ellis, K. A., Taddei, K., Martins, R. N., Masters, C. L., Ames, D. J., et al. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.06.008 · Cited by 34
Chan, D., Suk, H., Jackson, B., Milman, N., Stark, D., Klerman, E. B., Kitchener, E. G., Avalos, V. S. F., Banerjee, A., Beach, S. D., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3846540 · Cited by 37
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Hansen, N. W., Webb, J. L., Troise, L., Olsson, C., Tomasevic, L., Brinza, O., Achard, J., Staacke, R., Kieschnick, M., Meijer, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39539-y · Cited by 35
Mori, T., Maeda, J., Shimada, H., Higuchi, M., Shinotoh, H., Ueno, S., & Suhara, T. (2012) · Psychogeriatrics · doi:10.1111/j.1479-8301.2012.00409.x · Cited by 35
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 38
Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Stella, F., & Gattaz, W. F. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-3505 · Cited by 33
Joly‐Amado, A., Davtyan, H., Serraneau, K. S., Jules, P., Zitnyar, A., Pressman, E., Zagorski, K., Antonyan, T., Hovakimyan, A., Paek, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104636 · Cited by 33
Predicting diagnosis 4 years prior to Alzheimer’s disease incident
Qiu, A., Xu, L., & Liu, C. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102993 · Cited by 35
Okonkwo, O. C., Oh, J. M., Koscik, R. L., Jonaitis, E. M., Cleary, C. A., Dowling, N. M., Bendlin, B. B., LaRue, A. A., Hermann, B. P., Barnhart, T. E., et al. (2014) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617714000113 · Cited by 32
A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease
Peters, K. R., Beattie, B. L., Feldman, H., & Illes, J. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.12.001 · Cited by 38
Amyloid PET Ligands for Dementia
Villemagne, V. L., & Rowe, C. C. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.008 · Cited by 32
Kravitz, E., Gaisler-Salomon, I., & Biegon, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081244 · Cited by 30
“does not correlate with cognitive decline or atrophy [6,7] and amyloid-antibody-induced reductions in amyloid load detected by [11C]PIB did not result in clinical benefit [8].”
BackgroundNew Molecular Targets for PET and SPECT Imaging in Neurodegenerative Diseases
Benadiba, M., Luurtsema, G., Wichert‐Ana, L., Buchpiguel, C. A., & Busatto, G. F. (2012) · Brazilian Journal of Psychiatry · doi:10.1016/j.rbp.2012.07.002 · Cited by 178
Diagnosis of Alzheimer's disease in Brazil: Supplementary exams
Caramelli, P., Teixeira, A. L., Buchpiguel, C. A., Lee, H. W., LIVRAMENTO, J. A., Fernandez, L. L., & Anghinah, R. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05030004 · Cited by 39
The Role of Synaptic Dysfunction in Alzheimer’s Disease
Pei, Y. A., Davies, J., Zhang, M., & Zhang, H. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191334 · Cited by 31
Stylianaki, I., Polizopoulou, Z. S., Theodoridis, A. M., Koutouzidou, G., Baka, R. D., & Papaioannou, N. G. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15812 · Cited by 34
Beta-amyloid burden predicts poorer mnemonic discrimination in cognitively normal older adults
Webb, C. E., Foster, C. M., Horn, M. M., Kennedy, K. M., & Rodrigue, K. M. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117199 · Cited by 32
Hu, Y., Boonstra, J. T., McGurran, H., Stormmesand, J., Sluiter, A. A., Balesar, R. A., Verwer, R. W. H., Swaab, D. F., & Bao, A. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12729 · Cited by 30
Tateno, A., Sakayori, T., Kawashima, Y., Higuchi, M., Suhara, T., Mizumura, S., Mintun, M. A., Skovronsky, D., Honjo, K., Ishihara, K., et al. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4173 · Cited by 31
Yotter, R. A., Doshi, J. J., Clark, V., Sojkova, J., Zhou, Y., Wong, D. F., Ferrucci, L., Resnick, S. M., & Davatzikos, C. A. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.030 · Cited by 31
Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement
Hampel, H., & Lista, S. (2013) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0003-1 · Cited by 29
The temporal lobe in typical and atypical Alzheimer disease
Migliaccio, R., & Cacciamani, F. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823493-8.00004-3 · Cited by 33
Magnetic Resonance Imaging Based Clinical Research in Alzheimer's Disease
Fayed, N. M., Modrego, P. J., Salinas, G. R., & Gazulla, J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111292 · Cited by 29
Getting Past “g”: Testing a New Model of Dementing Processes in Persons Without Dementia
Royall, D. R., & Palmer, R. F. (2012) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.11040078 · Cited by 29
Ischemia signalling to Alzheimer-related genes
Pluta, R. M., Kocki, J., Maciejewski, R., Ułamek-Kozioł, M., Jabłoński, M., Bogucka‐Kocka, A., & Czuczwar, S. J. (2012) · Folia Neuropathologica · doi:10.5114/fn.2012.32362 · Cited by 30
Zhu, W., Wang, Y., Xie, D., Cheng, L., Wang, P., Zeng, Q., Li, M., & Zhao, Y. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00257 · Cited by 29
Distinct Brain Regions in Physiological and Pathological Brain Aging
Lee, J. S., Park, Y. H., Park, S., Yoon, U., Choe, Y. S., Cheon, B. K., Hahn, A., Cho, S. H., Kim, S. J., Kim, J. P., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00147 · Cited by 30
Appraisal of Cognition in Preclinical Alzheimer’s Disease: A Conceptual Review
Knopman, D. S., & Caselli, R. J. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.5 · Cited by 26
Self-citationAn overview of biomarkers in Alzheimer′s disease
Mathuranath, P. S., & Wattamwar, P. R. (2010) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.74256 · Cited by 31
Decreased hippocampal metabolism in high‐amyloid mild cognitive impairment
Hanseeuw, B. J., Schultz, A. P., Betensky, R. A., Sperling, R. A., & Johnson, K. A. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.2357 · Cited by 29
Alzheimer disease biomarkers and insights into mild cognitive impairment
Knopman, D. S. (2013) · Neurology · doi:10.1212/wnl.0b013e31828728ac · Cited by 28
Self-citationDrug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
Declercq, L., Vandenberghe, R. R., Laere, K. V., Verbruggen, A., & Bormans, G. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00088 · Cited by 31
Thabtah, F., Spencer, R., & Ye, Y. (2020) · Health Information Science and Systems · doi:10.1007/s13755-020-00114-8 · Cited by 30
Manipulation of the diet–microbiota–brain axis in Alzheimer’s disease
Lee, D. D., Lee, V. M. ‐., & Hur, S. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042865 · Cited by 29
The relative efficiency of time-to-threshold and rate of change in longitudinal data
Donohue, M. C., Gamst, A. C., Thomas, R. G., Xu, R., Beckett, L., Petersen, R. C., Weiner, M. W., & Aisen, P. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.04.007 · Cited by 27
Self-citationΒ-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review
Chung, J. K., Nakajima, S., Plitman, E., Iwata, Y., Uy, D., Gerretsen, P., Caravaggio, F., Chakravarty, M. M., & Graff‐Guerrero, A. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.03.013 · Cited by 27
Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression
Chen, X., Zhou, Y., Wang, R., Cao, H., Reid, S., Gao, R., Han, D., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154406 · Cited by 27
Knopman, D. S., Jack, C. R., Lundt, E. S., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.003 · Cited by 26
Self-citationGagliardi, G. P., for the INSIGHT-preAD study group, Epelbaum, S., Houot, M., Bakardjian, H., Boukadida, L., Revillon, M., Dubois, B., Barba, G. D., & Corte, V. L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180966 · Cited by 28
Ethical issues in Alzheimer’s disease: an overview
Leuzy, A., & Gauthier, S. G. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.38 · Cited by 31
Fraile-Ramos, J., Garrit, A., Reig-Vilallonga, J., & Giménez-Llort, L. (2023) · Cells · doi:10.3390/cells12111517 · Cited by 26
Lee, J., Renslo, J., Wong, K., Clifford, T. G., Beutler, B. D., Kim, P. E., & Gholamrezanezhad, A. (2024) · Diagnostics · doi:10.3390/diagnostics14060585 · Cited by 31
Zinc utilization by microglia in Alzheimer’s disease
Shippy, D. C., Oliai, S. F., & Ulland, T. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107306 · Cited by 28
Amyloid imaging in prodromal Alzheimer's disease
Ossenkoppele, R., van Berckel, B. N. M., & Prins, N. D. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt88 · Cited by 27
Ferreira, L. K., Tamashiro-Duran, J. H., Squarzoni, P., Duran, F., Alves, T. C. T. F., Buchpiguel, C. A., & Busatto, G. F. (2014) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1275 · Cited by 27
A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer’s Disease (REMEMBER)
Niemantsverdriet, E., Ribbens, A., Bastin, C., Benoit, F., Bergmans, B. A., Bier, J., Bladt, R., Claes, L., Deyn, P. P. D., Deryck, O., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171140 · Cited by 28
Lanzi, A. M., Saylor, A. K., & Cohen, M. L. (2022) · American Journal of Speech-Language Pathology · doi:10.1044/2022_ajslp-21-00266 · Cited by 30
Björk, L., Klingstedt, T., & Nilsson, K. P. R. (2023) · ChemBioChem · doi:10.1002/cbic.202300044 · Cited by 28
Grydeland, H., Westlye, L. T., Walhovd, K. B., & Fjell, A. M. (2012) · Human Brain Mapping · doi:10.1002/hbm.22103 · Cited by 27
Recent Advances in Imaging Alzheimer's Disease
Braskie, M. N., Toga, A. W., & Thompson, P. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129016 · Cited by 28
Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men
Cho, H., Kim, C., Kim, Y. J., Ye, B. S., Kim, Y. J., Jung, N., Son, T. O., Cho, E. B., Jang, H., Lee, J. H., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12816 · Cited by 29
Pittsburgh compound B retention and progression of cognitive status – a meta‐analysis
Chen, X., Li, M., Wang, S., Zhu, H., Xiong, Y., & Liu, X. (2014) · European Journal of Neurology · doi:10.1111/ene.12398 · Cited by 22
Hess, N., & Smart, N. A. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00048 · Cited by 28
Alzheimer's disease biomarkers in animal models: closing the translational gap.
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Europe PMC (PubMed Central) · Cited by 31
Sarkar, S., Bhui, U., Kumar, B., Ashique, S., Kumar, P., Sharma, H., Bhowmick, M., Pal, R., & Kumar, T. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822329981241007105405 · Cited by 31
Metadata
- Authors
- Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-31
- Volume
- 132
- Issue
- 5
- Pages
- 1355-1365
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2677798
- OpenAlex
- W2133719476
- Cited by
- 1,099
- References
- 83
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 34 · 2023: 51 · 2022: 45 · 2021: 49 · 2020: 60 · 2019: 54 · 2018: 62 · 2017: 46 · 2016: 56 · 2015: 69 · 2014: 73 · 2013: 94 · 2012: 116
- FWCI
- 71.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Mayo Foundation for Medical Education and Research (AG16574)
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institute on Aging (R01AG11378, P01AG010491, P50‐AG16574, U01AG06786, AG 024904, R01AG027342, U01AG006786, R01AG011378, P30AG019610, U19AG010483, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, amyloid deposition, neurodegeneration, brain atrophy, ventriculomegaly, Pittsburgh compound B PET, serial imaging, amyloid plaques, cognitive decline, Alzheimer's Disease Neuroimaging Initiative, brain atrophy rate
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Atrophy, Brain, Carbon Radioisotopes, Cognition Disorders, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Time Factors, Case-Control Studies, Amyloid beta-Peptides, Statistics, Nonparametric, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.